Showing 2631-2640 of 5956 results for "".
- Novartis Terminates Three Trials of Beovu Despite Meeting Primary Endpoint of MERLIN Trialhttps://modernod.com/news/novartis-terminates-three-trials-of-beovu-despite-meeting-primary-endpoint/2479246/Novartis reported that Beovu met its primary endpoint in the phase 3 MERLIN trial, but decided to terminate the study due to higher rates of intraocular inflammation with frequent dosing intervals. Novartis reported the first interpretable year 1 results of the MERLIN trial, a 2-year study
- Samsara Vision: Patients Blinded by Macular Degeneration May Benefit From Implant Technologyhttps://modernod.com/news/samsara-vision-reports-that-patients-blinded-by-macular-degeneration-benefit-from-milestone-in-implant-technology/2479242/Samsara Vision announced the first successful clinical cases in Europe using their smaller-incision new-generation implantable miniature telescope (SING IMT) for people living with late-stage age-related macular degeneration (AMD). The SING IMT, performed with the TSert delivery system, was succe
- CooperVision DreamLite Ortho-K Lenses Gain European Approval for Slowing Progression of Myopiahttps://modernod.com/news/coopervision-dreamlite-ortho-k-lenses-gain-european-approval-for-slowing-progression-of-myopia/2479240/CooperVision Specialty EyeCare’s Procornea DreamLite night lenses have received European approval for slowing the progression of myopia in children and young adults. The orthokeratology contact lens is the latest CooperVision myopia control product to gain the CE Mark, joining EyeDream and Parago
- Vyluma Launches With Myopia Treatment In Phase 3 Developmenthttps://modernod.com/news/vyluma-inc-launches-with-robust-opthalmic-portfolio-leading-with-a-pharmaceutical-treatment-in-phase-iii-for-myopia/2479239/Vyluma announced its establishment as a wholly-owned subsidiary of Nevakar Inc., focusing on pharmaceutical ophthalmic solutions. The pipeline of novel therapies is led by NVK002, a pharmaceutical atropine eye drop to slow the progression of myopia in children. NVK002 is currently in late phase 3
- Okayama University Research: High Levels of Television Exposure Affect Visual Acuity in Childrenhttps://modernod.com/news/okayama-university-research-high-levels-of-television-exposure-affect-visual-acuity-in-children/2479236/In a study reported in the Japanese Journal of Ophthalmology, researchers from Okayama University show that long hours in front of the television in children under 3 years of age lead to increased eyesight concerns during later years. It is ingrained in parents to curtail the hours
- EU Signs Deal With BioNTech, Pfizer for Further 1.8 Billion COVID-19 Vaccine Doseshttps://modernod.com/news/eu-signs-deal-with-biontech-pfizer-for-further-1-8-billion-covid-19-vaccine-doses/2479234/The European Commission announced the signing of a third contract with BioNTech and Pfizer for the supply of up to 1.8 billion COVID-19 vaccine doses between the end of this year and 2023, according to a FirstWord report. The deal, which had been agreed earlier this month, allows for the purchase
- The Children’s Eye Foundation of AAPOS Debuts “THE CURIOUS EYE” Interactive Storybookhttps://modernod.com/news/the-childrens-eye-foundation-of-aapos-debuts-the-curious-eye-interactive-storybook/2479230/The Children’s Eye Foundation of AAPOS unveiled the world’s first interactive children’s book to help screen for color vision deficiency (CVD), commonly known as color blindness. The foundation has posted a free digital version of THE CURIOUS EYE at
- Prevent Blindness Declares Second Annual Inherited Retinal Disease (IRD) Genetic Testing Week as May 16-22https://modernod.com/news/prevent-blindness-declares-second-annual-inherited-retinal-disease-ird-genetic-testing-week-as-may-16-22/2479209/Prevent Blindness has declared the second annual “Inherited Retinal Disease (IRD) Genetic Testing Week” as May 16-22, 2021. As part of this initiative, Prevent Blindness will be posting a series of educational graphics on its social media channels, including Facebook, Twitter, and Instagram.
- NUST MISIS Scientists Say They Developed a Safe Drug to Treat Eye Inflammationhttps://modernod.com/news/nust-misis-scientists-say-they-developed-a-safe-drug-to-treat-eye-inflammation/2479203/A Russian-American research team from The National University of Science and Technology MISIS has presented a new therapeutic method using nanoparticles of an antioxidant enzyme, developed specifically for the eyes. It relieves inflammation and repairs tissue without causing side effects: irritat
- Lumenis Named “Best Overall Medical Device Company” in 2021 MedTech Breakthrough Awardshttps://modernod.com/news/lumenis-named-best-overall-medical-device-company-in-2021-medtech-breakthrough-awards/2479201/Lumenis announced that it has been selected as the “Best Overall Medical Device Company” in the MedTech Breakthrough Awards. MedTech Breakthrough is an independent market intelligence organization that honors excellence and recognizes the top companies, technologies and products in the global he